CohBar Investor Relations Material
Latest events
M&A Announcement
CohBar
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from CohBar Inc
Access all reports
CohBar Inc. is a clinical-stage biotechnology company focused on developing therapeutics based on peptides derived from mitochondrial DNA. The company’s research centers on leveraging its proprietary mitochondrial peptide technology platform to address chronic and age-related diseases. CohBar’s pipeline targets conditions such as metabolic disorders, fibrotic diseases, cancer, and neurodegenerative diseases. The company is headquartered in Menlo Park, California, and its shares are listed on the NASDAQ Stock Exchange.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
CWBR
Country
🇺🇸 United States